The Outcome Reduction with an Initial Glargine Intervention ( ORIGIN ) trial randomised 12,537 people with diabetes , impaired glucose tolerance or impaired fasting glucose to receive standard glycaemic care or standard care with the addition of basal insulin glargine ( A21Gly , B31Arg , B32Arg human insulin ) , targeting a fasting plasma glucose level 5.3 mmol/l .